Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; VHH; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| SKU | Size | Availability | Price | Qty |
|---|---|---|---|---|
| Ab170617-100μg | 100μg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $89.90 | |
| Ab170617-1mg | 1mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $417.90 | |
| Ab170617-5mg | 5mg | Available within 4-8 weeks(?) Items will be manufactured post-order and can take 4-8 weeks. Thank you for your patience! | $867.90 | |
| Ab170617-10mg | 10mg | Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding. | $1,407.90 |
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; VHH; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
| Product Name | Envafolimab (anti-PD-L1) - Primary antibody, for ELISA,Functional Assay,Kinetics (BLI),Kinetics (SPR),Flow Cyt various applications, specific to CD274, >95%, high purity, VHH |
|---|---|
| Synonyms | B7 H1 antibody|B7 homolog 1 antibody|B7-H1 antibody|B7H antibody|B7H1 antibody|CD 274 antibody|CD-274 antibody|CD274 antibody|CD274 antigen antibody|CD274 molecule antibody|MGC142294 antibody|MGC142296 antibody|OTTHUMP00000021029 antibody|PD L1 antibody|P |
| Specifications & Purity | ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot |
| Specificity | CD274 |
| Application | ELISA,Functional Assay,Kinetics (BLI),Kinetics (SPR),Flow Cyt |
| Conjugation | Unconjugated |
| Grade | Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated |
| Action Type | BINDING AGENT |
| Mechanism of action | BINDING AGENT of Programmed cell death 1 ligand 1 binding agent |
| Product Description | Envafolimab is a humanized anti- PD-L1 antibody. Envafolimab blocks interaction between PD-L1 and PD-1 with an IC50 value of 5.25 nM. Envafolimab has the potential for the research of solid tumors.
Purity >95% (SDS-PAGE&SEC) Endotoxin Level < 1.0EU/mg |
| Antibody Type | Primary antibody |
|---|---|
| Clonality | Recombinant |
| Isotype | VHH |
| SDS-PAGE | 80 kDa |
| Purification Method | Protein A purified |
| Purity | >95% |
| Source | CHO supernatant |
| Form | Liquid |
| Concentration | Lot by Lot |
| Storage Temp | Store at -80°C,Avoid repeated freezing and thawing |
| Shipped In | Ice chest + Ice pads |
| Stability And Storage | Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle. |
| CAS | 2102192-68-5 |
Envafolimab (anti-PD-L1) (Ab170617) - Flow Cytometry
Flow Cytometry analysis of MDA-MB-231 cells labelling PD-L1 (red) with Envafolimab (anti-PD-L1) (Ab170617). Goat Anti-Human IgG (PE) (Ab175838) at a dilution of 1/1000 was used as the secondary antibody. Blue - Isotype control, human IgG (Ab170213). Black - Unlabelled control, cells without incubation with primary antibody.
Envafolimab (anti-PD-L1) (Ab170617) - SEC
The purity of Envafolimab (anti-PD-L1) (Ab170617) is more than 95% verified by HPLC.
Envafolimab (anti-PD-L1) (Ab170617) - ELISA
Immobilized PD-L1-His at 2 μg/mL can bind Envafolimab (anti-PD-L1) (Ab170617) with the EC₅₀ of 3.57 ng/mL.
| Activity Type | Activity Value -log(M) | Mechanism of Action | Activity Reference | Publications (PubMed IDs) |
|---|
| IMGT/mAb-DB | 934 |
|---|
Enter Lot Number to search for COA:
To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section
| Lot Number | Certificate Type | Date | Item |
|---|---|---|---|
 ZJ24F0404941 | Certificate of Analysis | Apr 26, 2024 | Ab170617 |
| ZJ24F0404940 | Certificate of Analysis | Apr 26, 2024 | Ab170617 |
| ZJ24F0404942 | Certificate of Analysis | Apr 26, 2024 | Ab170617 |
| ZJ23F0900989 | Certificate of Analysis | Sep 11, 2023 | Ab170617 |
| ZJ23F0900988 | Certificate of Analysis | Sep 11, 2023 | Ab170617 |
| 1. Zhang F, Wei H, Wang X, Bai Y, Wang P, Wu J, Jiang X, Wang Y, Cai H, Xu T et al.. (2017) Structural basis of a novel PD-L1 nanobody for immune checkpoint blockade.. Cell Discov, 3 (3): (17004). [PMID:28280600] |
| 2. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS et al.. (2013) Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.. N Engl J Med, 369 (2): (134-44). [PMID:23724846] |
| 3. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ, Malenkovich N, Okazaki T, Byrne MC et al.. (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation.. J Exp Med, 192 (7): (1027-34). [PMID:11015443] |
| 4. Lee HT, Lee JY, Lim H, Lee SH, Moon YJ, Pyo HJ, Ryu SE, Shin W, Heo YS. (2017) Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab.. Sci Rep, 7 (1): (5532). [PMID:28717238] |
| 5. Lin DY, Tanaka Y, Iwasaki M, Gittis AG, Su HP, Mikami B, Okazaki T, Honjo T, Minato N, Garboczi DN. (2008) The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors.. Proc Natl Acad Sci USA, 105 (8): (3011-6). [PMID:18287011] |
| 6. Zak KM, Kitel R, Przetocka S, Golik P, Guzik K, Musielak B, Dömling A, Dubin G, Holak TA. (2015) Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1.. Structure, 23 (12): (2341-2348). [PMID:26602187] |
| 7. Cheng B, Ren Y, Niu X, Wang W, Wang S, Tu Y, Liu S, Wang J, Yang D, Liao G, Chen J.. (2020) Discovery of Novel Resorcinol Dibenzyl Ethers Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction as Potential Anticancer Agents.. J Med Chem, 63 (15): (8338-8358). [PMID:32667799] |
| 8. He, Xian-hui XH, Xu, Li-hui LH and Liu, Yi Y.. (2005) Identification of a novel splice variant of human PD-L1 mRNA encoding an isoform-lacking Igv-like domain.. Acta pharmacologica Sinica, [PMID:15780196] |
| 9. Rosenberg, Jonathan E JE and 30 more authors.. (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.. Lancet (London, England), (7): [PMID:26952546] |
| 10. Kataoka, Keisuke K and 43 more authors.. (2016) Aberrant PD-L1 expression through 3'-UTR disruption in multiple cancers.. Nature, (16): [PMID:27281199] |
| 11. and Markham, Anthony A.. (2016) Atezolizumab: First Global Approval.. Drugs, [PMID:27412122] |
| 12. Bellmunt, Joaquin J, Powles, Thomas T and Vogelzang, Nicholas J NJ.. (2017) A review on the evolution of PD-1/PD-L1 immunotherapy for bladder cancer: The future is now.. Cancer treatment reviews, [PMID:28214651] |
| 13. Mezzadra, Riccardo R and 18 more authors.. (2017) Identification of CMTM6 and CMTM4 as PD-L1 protein regulators.. Nature, (7): [PMID:28813410] |
| 14. Burr, Marian L ML and 23 more authors.. (2017) CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity.. Nature, (7): [PMID:28813417] |
| 15. Faiena, Izak I and 5 more authors.. (2018) Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma.. Drug design, development and therapy, [PMID:29416316] |
| 16. Dong, H H, Zhu, G G, Tamada, K K and Chen, L L.. (1999) B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion.. Nature medicine, [PMID:10581077] |
